$CPRX
Catalyst Pharmaceuticals Inc

2023 Q2 Form 10-Q Financial Statement

#000119312523140701 Filed on May 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $99.58M $85.37M $43.09M
YoY Change 87.49% 98.12% 42.63%
Cost Of Revenue $12.05M $9.946M $5.890M
YoY Change 57.6% 68.86% 25.85%
Gross Profit $87.54M $75.42M $37.20M
YoY Change 92.52% 102.75% 45.76%
Gross Profit Margin 87.9% 88.35% 86.33%
Selling, General & Admin $28.40M $29.72M $16.43M
YoY Change 119.82% 80.88% 29.17%
% of Gross Profit 32.44% 39.4% 44.17%
Research & Development $3.954M $3.562M $3.403M
YoY Change -0.73% 4.67% 13.06%
% of Gross Profit 4.52% 4.72% 9.15%
Depreciation & Amortization $8.570M $69.00K $34.00K
YoY Change 23062.16% 102.94% -66.0%
% of Gross Profit 9.79% 0.09% 0.09%
Operating Expenses $32.35M $33.28M $19.83M
YoY Change 91.41% 67.8% 26.16%
Operating Profit $46.70M $35.61M $17.37M
YoY Change 63.46% 105.05% 77.2%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.813M $1.704M $93.00K
YoY Change -659.57% 1732.26% 16.25%
Pretax Income $48.51M $37.31M $17.46M
YoY Change 71.75% 113.72% 76.71%
Income Tax $10.75M $7.745M $4.218M
% Of Pretax Income 22.16% 20.76% 24.16%
Net Earnings $37.76M $29.57M $13.24M
YoY Change 74.67% 123.31% 72.86%
Net Earnings / Revenue 37.92% 34.64% 30.73%
Basic Earnings Per Share $0.36 $0.28 $0.13
Diluted Earnings Per Share $0.33 $0.26 $121.4K
COMMON SHARES
Basic Shares Outstanding 106.1M 105.7M 102.8M
Diluted Shares Outstanding 113.7M 114.0M 109.0M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $178.8M $148.2M $197.8M
YoY Change -19.02% -25.05% 38.03%
Cash & Equivalents $178.8M $148.2M $178.4M
Short-Term Investments $19.42M
Other Short-Term Assets $8.634M $6.934M $5.016M
YoY Change 99.26% 38.24% -39.57%
Inventory $10.75M $10.33M $7.827M
Prepaid Expenses
Receivables $42.80M $33.40M $10.55M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $241.0M $198.9M $221.2M
YoY Change -0.66% -10.07% 36.96%
LONG-TERM ASSETS
Property, Plant & Equipment $1.203M $1.285M $3.882M
YoY Change -68.44% -66.9% -9.72%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $23.49M $20.24M $21.90M
YoY Change 12.18% -7.57% -30.26%
Total Long-Term Assets $202.9M $208.3M $25.78M
YoY Change 719.88% 708.02% -27.78%
TOTAL ASSETS
Total Short-Term Assets $241.0M $198.9M $221.2M
Total Long-Term Assets $202.9M $208.3M $25.78M
Total Assets $443.9M $407.2M $247.0M
YoY Change 66.06% 64.89% 25.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.421M $3.391M $5.139M
YoY Change 90.97% -34.01% 97.65%
Accrued Expenses $48.08M $53.32M $15.28M
YoY Change 165.82% 248.99% 42.79%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $52.50M $56.71M $22.94M
YoY Change 133.47% 147.23% 59.29%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $12.72M $13.39M $3.813M
YoY Change 241.19% 251.14% -7.0%
Total Long-Term Liabilities $12.72M $13.39M $3.813M
YoY Change 241.19% 251.14% -7.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $52.50M $56.71M $22.94M
Total Long-Term Liabilities $12.72M $13.39M $3.813M
Total Liabilities $68.60M $73.57M $26.75M
YoY Change 161.67% 175.0% 43.82%
SHAREHOLDERS EQUITY
Retained Earnings $117.2M $79.43M
YoY Change
Common Stock $107.0K $106.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $375.3M $333.7M $220.2M
YoY Change
Total Liabilities & Shareholders Equity $443.9M $407.2M $247.0M
YoY Change 66.06% 64.89% 25.24%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income $37.76M $29.57M $13.24M
YoY Change 74.67% 123.31% 72.86%
Depreciation, Depletion And Amortization $8.570M $69.00K $34.00K
YoY Change 23062.16% 102.94% -66.0%
Cash From Operating Activities $30.75M $12.07M $8.478M
YoY Change 17.42% 42.37% 122.52%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $74.00K $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$162.3M $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 -$162.4M $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net -$1.551M
YoY Change -916.32%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -214.0K 149.0K -1.551M
YoY Change -92.85% -109.61% -916.32%
NET CHANGE
Cash From Operating Activities 30.75M 12.07M 8.478M
Cash From Investing Activities 0.000 -162.4M 0.000
Cash From Financing Activities -214.0K 149.0K -1.551M
Net Change In Cash 30.54M -150.1M 6.927M
YoY Change -6.15% -2267.58% -338.04%
FREE CASH FLOW
Cash From Operating Activities $30.75M $12.07M $8.478M
Capital Expenditures $0.00 $74.00K $0.00
Free Cash Flow $30.75M $12.00M $8.478M
YoY Change 17.29% 41.5% 79.62%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001369568
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-33057
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
CATALYST PHARMACEUTICALS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
76-0837053
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
355 Alhambra Circle
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 801
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Coral Gables
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33134
CY2023Q1 dei City Area Code
CityAreaCode
305
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
420-3200
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2023Q1 dei Trading Symbol
TradingSymbol
CPRX
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
106076959
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#LiabilitiesCurrent
CY2023Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#LiabilitiesCurrent
CY2023Q1 cprx Minimum Amortization Period Of Compensation Cost On Straight Line Basis
MinimumAmortizationPeriodOfCompensationCostOnStraightLineBasis
P1Y
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
148247000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
298395000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
33402000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10439000
CY2023Q1 us-gaap Inventory Net
InventoryNet
10328000
CY2022Q4 us-gaap Inventory Net
InventoryNet
6805000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6934000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5167000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
198911000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
320806000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2706000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2770000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1285000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
847000
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
184083000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
32471000
CY2023Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
20242000
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
18736000
CY2023Q1 us-gaap Assets
Assets
407227000
CY2022Q4 us-gaap Assets
Assets
375630000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3391000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3975000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53318000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53613000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
56709000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
57588000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3468000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3557000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
13389000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
14064000
CY2023Q1 us-gaap Liabilities
Liabilities
73566000
CY2022Q4 us-gaap Liabilities
Liabilities
75209000
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
105938292
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
105938292
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
105263031
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
105263031
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
106000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
105000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
254114000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
250430000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
79430000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
49862000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
11000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
24000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
333661000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
300421000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
407227000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
375630000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
85366000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
43089000
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9946000
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5890000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3562000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3403000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
29718000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16430000
CY2023Q1 cprx Amortization Expenses Of Intangible Asset
AmortizationExpensesOfIntangibleAsset
6531000
CY2022Q1 cprx Amortization Expenses Of Intangible Asset
AmortizationExpensesOfIntangibleAsset
0
CY2023Q1 cprx Operating Expense
OperatingExpense
49757000
CY2022Q1 cprx Operating Expense
OperatingExpense
25723000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
35609000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
17366000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1704000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
93000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
37313000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
17459000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7745000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4218000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
29568000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
13241000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.26
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
105561229
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102781771
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113986129
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109041096
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
29568000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
13241000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
5000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
94000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-13000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-305000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
29555000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
12936000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
300421000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2177000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1270000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
715000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-477000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-13000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
29568000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
333661000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
206831000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1623000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1102000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
280000
CY2022Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
2551000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-305000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
13241000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
220221000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
29568000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
13241000
CY2023Q1 us-gaap Depreciation
Depreciation
69000
CY2022Q1 us-gaap Depreciation
Depreciation
34000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2892000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1903000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6531000
CY2023Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
1519000
CY2022Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-1901000
CY2022Q1 cprx Change In Accrued Interest And Accretion Of Discount On Investments
ChangeInAccruedInterestAndAccretionOfDiscountOnInvestments
2000
CY2023Q1 cprx Non Cash Change In Right Of Use Asset
NonCashChangeInRightOfUseAsset
64000
CY2022Q1 cprx Non Cash Change In Right Of Use Asset
NonCashChangeInRightOfUseAsset
60000
CY2023Q1 cprx Acquired Inventory Samples Expensed From Asset Acquisition
AcquiredInventorySamplesExpensedFromAssetAcquisition
130000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
22963000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3933000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-577000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-43000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
191000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
563000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-584000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2371000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2422000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6504000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-82000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-73000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
12070000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
8478000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
74000
CY2023Q1 cprx Payment In Connection With Asset Acquisition
PaymentInConnectionWithAssetAcquisition
162293000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-162367000
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
477000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1270000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000000
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2551000
CY2023Q1 cprx Payment Of Liabilities Arising From Asset Acquisition
PaymentOfLiabilitiesArisingFromAssetAcquisition
644000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
149000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1551000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-150148000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
6927000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
298395000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
171445000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
148247000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
178372000
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2022Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
41000
CY2022Q1 cprx Proceeds From Exercise Of Stock Options Not Yet Settled At End Of Period
ProceedsFromExerciseOfStockOptionsNotYetSettledAtEndOfPeriod
102000
CY2023Q1 cprx Liabilities Arising From Asset Acquisition
LiabilitiesArisingFromAssetAcquisition
1915000
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Organization and Description of Business. </div></div></td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Catalyst Pharmaceuticals, Inc. and subsidiary (collectively, the Company) is a commercial-stage biopharmaceutical company focused on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing,</div> developing, and commercializing novel medicines for patients living with rare diseases and diseases that are difficult to treat. With exceptional patient focus, is committed to developing and commercializing innovative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class</div></div> medicines that address rare neurological and epileptic diseases. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Catalyst’s New Drug Application for FIRDAPSE<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div> (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome (LEMS) was approved in 2018 by the U.S. Food &amp; Drug Administration (FDA), and FIRDAPSE<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div> is commercially available in the United States as a treatment for adults with LEMS. Further, Canada’s national healthcare regulatory agency, Health Canada, approved the use of FIRDAPSE<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div> for the treatment of adult patients in Canada with LEMS in 2020 and FIRDAPSE<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div> is commercially available in Canada for the treatment of patients with LEMS through a license and supply agreement with KYE Pharmaceuticals. Finally, in the third quarter of 2022, the FDA approved the Company’s sNDA approving an expansion of the FIRDAPSE<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div> label to include pediatric patients (ages six and older). </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December 17, 2022, the Company entered into an asset purchase agreement with Eisai Co., Ltd. (Eisai) for the acquisition of the United States rights to FYCOMPA<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div> (perampanel) CIII, a prescription medication used alone or in combination with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. The Company closed the acquisition of FYCOMPA<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div> on January 24, 2023 and the Company is marketing FYCOMPA<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div> in the United States. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since inception, the Company has devoted substantially all its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets, raising capital, and selling its products. The Company incurred operating losses in each period from inception and started reporting operating income during the year ended December 31, 2019. The Company has been able to fund its cash needs to date through offerings of its securities and from revenues from sales of its products. See Note 15 (Stockholders’ Equity). </div></div></div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Capital Resources </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there can be no assurance, based on currently available information, the Company estimates that it has sufficient resources to support its operations for at least the next 12 months from the issuance date of this report. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may raise funds in the future through public or private equity offerings, debt financings, corporate collaborations, governmental research grants or other means. The Company may also seek to raise new capital to fund additional business development activities, even if it has sufficient funds for its planned operations. Any sale by the Company of additional equity or convertible debt securities could result in dilution to the Company’s current stockholders. There can be no assurance that any required additional funding will be available to the Company at all or available on terms acceptable to the Company. Further, to the extent that the Company raises additional funds through collaborative arrangements, it may be necessary to relinquish some rights to the Company’s drug candidates or grant sublicenses on terms that are not favorable to the Company. If the Company is not able to secure additional funding when needed, the Company may have to delay, reduce the scope of, or eliminate one or more research and development programs, which could have an adverse effect on the Company’s business. </div></div></div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are numerous aspects of the coronavirus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(COVID-19)</div> pandemic that have adversely affected the Company’s business since the beginning of the pandemic. The Company closely monitors the impact of the pandemic on all aspects of its business and takes steps, wherever possible, to lessen those impacts. However, the Company is unable to predict the impact that the coronavirus pandemic will have on its business in future periods. </div>
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">c.</div></div></td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">USE OF ESTIMATES.</div></div> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. </div></td></tr></table>
CY2023Q1 cprx Maximum Maturity Period Of Cash And Cash Equivalent
MaximumMaturityPeriodOfCashAndCashEquivalent
three months
CY2023Q1 us-gaap Long Term Investments
LongTermInvestments
0
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
0
CY2022Q4 cprx Other Noncurrent Accrued Expenses And Other Liabilities
OtherNoncurrentAccruedExpensesAndOtherLiabilities
17621000
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q1 cprx Share Repurchases
ShareRepurchases
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">o.</div></div></td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SHARE REPURCHASES.</div></div> In March 2021, the Company’s Board of Directors approved a share repurchase program that authorizes the repurchase of up to $<div style="letter-spacing: 0px; top: 0px;;display:inline;">40</div> million of the Company’s common stock. </div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company accounts for share repurchases by charging the excess of the repurchase price over the repurchased common stock’s par value entirely to retained earnings (accumulated deficit). All repurchased shares are retired and become authorized but unissued shares. The Company accrues for the shares purchased under the share repurchase plan based on the trade date. The Company may terminate or modify its share repurchase program at any time.<br/></div>
CY2023Q1 cprx Maximum Amortization Period Of Compensation Cost On Straight Line Basis
MaximumAmortizationPeriodOfCompensationCostOnStraightLineBasis
P3Y
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">t.</div></div></td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CONCENTRATION OF RISK. </div></div>The financial instruments that potentially subject the Company to concentration of credit risk are cash equivalents (i.e., money market funds), investments and accounts receivable, net. The Company places its cash and cash equivalents with high-credit quality financial institutions. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in these accounts. </div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company sells its product, FIRDAPSE<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">®</div>, in the United States through an exclusive distributor (its Customer) to SPs. Therefore, its distributor and SPs account for principally all of its trade receivables and net product revenues. The creditworthiness of its Customer is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for expected credit loss primarily based on the credit worthiness of its Customer, historical payment patterns, aging of receivable balances and general economic conditions. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March 31, 2023, the Company had two products, which makes it difficult to evaluate its current business, predict its future prospects, and forecast financial performance and growth. The Company had invested a significant portion of its efforts and financial resources in the development and commercialization of its lead product, FIRDAPSE<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div>. The Company expects FIRDAPSE<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div> and the recently acquired product FYCOMPA<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div> to constitute virtually all of the Company’s product revenue for the foreseeable future.</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company relies exclusively on third parties to formulate and manufacture FIRDAPSE<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div>, FYCOMPA<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div> and any future drug candidates. The commercialization of FIRDAPSE<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div>, FYCOMPA<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div>, and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those third parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company does not intend to establish its own manufacturing facilities. The Company is using the same third-party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and for the commercialization of FIRDAPSE<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div>. If the Company is unable to continue its relationships with one or more of these third-party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on one or more third-party contractors to manufacture the commercial supply of its drugs.</div></div></div>
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
570000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
105561229
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102781771
CY2023Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
8424900
CY2022Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
6259325
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113986129
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109041096
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1300000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2300000
CY2023Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">z.</div></div></div></td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RECLASSIFICATIONS.</div></div> Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation. </div></div></td></tr></table>
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
115785000
CY2023Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
14000
CY2023Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
0
CY2023Q1 cprx Amortized Cost Before Unrealized Gains And Losses
AmortizedCostBeforeUnrealizedGainsAndLosses
115771000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
105442000
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
32000
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
0
CY2022Q4 cprx Amortized Cost Before Unrealized Gains And Losses
AmortizedCostBeforeUnrealizedGainsAndLosses
105410000
CY2023Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2022Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
115785000
CY2023Q1 cprx Lessee Operating Lease Liabilities Payments Due After Year Four
LesseeOperatingLeaseLiabilitiesPaymentsDueAfterYearFour
2027000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4591000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
778000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3813000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
24000
CY2023Q1 us-gaap Other Comprehensive Income Loss Before Reclassifications Tax
OtherComprehensiveIncomeLossBeforeReclassificationsTax
13000
CY2023Q1 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-13000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
11000
CY2023Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
0
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
0
CY2023Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
5642000
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
5543000
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4686000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1262000
CY2023Q1 us-gaap Inventory Net
InventoryNet
10328000
CY2022Q4 us-gaap Inventory Net
InventoryNet
6805000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
CY2023Q1 cprx Prepaid Manufacturing Expense
PrepaidManufacturingExpense
1147000
CY2022Q4 cprx Prepaid Manufacturing Expense
PrepaidManufacturingExpense
1147000
CY2023Q1 us-gaap Prepaid Taxes
PrepaidTaxes
44000
CY2022Q4 us-gaap Prepaid Taxes
PrepaidTaxes
44000
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
871000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1224000
CY2023Q1 cprx Prepaid Subscription Fees
PrepaidSubscriptionFees
1057000
CY2022Q4 cprx Prepaid Subscription Fees
PrepaidSubscriptionFees
808000
CY2023Q1 cprx Prepaid Research Fee
PrepaidResearchFee
157000
CY2022Q4 cprx Prepaid Research Fee
PrepaidResearchFee
178000
CY2023Q1 cprx Prepaid Commercial Expenses
PrepaidCommercialExpenses
2585000
CY2022Q4 cprx Prepaid Commercial Expenses
PrepaidCommercialExpenses
592000
CY2023Q1 cprx Due From Collaborative And Licencing Arrangements
DueFromCollaborativeAndLicencingArrangements
213000
CY2022Q4 cprx Due From Collaborative And Licencing Arrangements
DueFromCollaborativeAndLicencingArrangements
354000
CY2023Q1 cprx Prepaid Conference And Travel Expenses
PrepaidConferenceAndTravelExpenses
525000
CY2022Q4 cprx Prepaid Conference And Travel Expenses
PrepaidConferenceAndTravelExpenses
234000
CY2023Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
335000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
586000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6934000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5167000
CY2023Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
5
CY2023Q1 cprx Operating Lease Liability Under Finance Leases
OperatingLeaseLiabilityUnderFinanceLeases
0
CY2023Q1 cprx Before Agreement Of Company Leased Spaces
BeforeAgreementOfCompanyLeasedSpaces
7800
CY2023Q1 cprx After Agreement Of Company Leased Spaces
AfterAgreementOfCompanyLeasedSpaces
10700
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3557000
CY2023Q1 cprx Asset Acquisation Due To Licensor Noncurrent
AssetAcquisationDueToLicensorNoncurrent
13389000
CY2022Q4 cprx Asset Acquisation Due To Licensor Noncurrent
AssetAcquisationDueToLicensorNoncurrent
14064000
CY2023Q1 cprx Other Noncurrent Accrued Expenses And Other Liabilities
OtherNoncurrentAccruedExpensesAndOtherLiabilities
16857000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
108000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
108000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
125000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
121000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
22000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
22000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2706000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2770000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
345000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
337000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3468000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3557000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3813000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3894000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y1M6D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y3M18D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0451
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
382000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
522000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
537000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
553000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
475000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
406000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1285000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
847000
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
191712000
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
7629000
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
184083000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
33569000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1098000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
32471000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
25462000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
33949000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
33949000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
33949000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
33949000
CY2023Q1 cprx Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
22825000
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
184083000
CY2023Q1 us-gaap Finite Lived Intangible Assets Remaining Amortization Period1
FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
P6Y8M12D
CY2022 us-gaap Finite Lived Intangible Assets Remaining Amortization Period1
FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
P14Y
CY2023Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2022Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2023Q1 cprx Accrued Non Clinical And Clinical Trial Expenses
AccruedNonClinicalAndClinicalTrialExpenses
290000
CY2022Q4 cprx Accrued Non Clinical And Clinical Trial Expenses
AccruedNonClinicalAndClinicalTrialExpenses
479000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5626000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1619000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2043000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5132000
CY2023Q1 cprx Accrued License Fees Current
AccruedLicenseFeesCurrent
7614000
CY2022Q4 cprx Accrued License Fees Current
AccruedLicenseFeesCurrent
20444000
CY2023Q1 cprx Accrued Purchases Current
AccruedPurchasesCurrent
146000
CY2022Q4 cprx Accrued Purchases Current
AccruedPurchasesCurrent
154000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
345000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
337000
CY2023Q1 cprx Accrued Variable Consideration
AccruedVariableConsideration
4748000
CY2022Q4 cprx Accrued Variable Consideration
AccruedVariableConsideration
3381000
CY2023Q1 cprx Accrued Charitable Contributions
AccruedCharitableContributions
1350000
CY2023Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
17949000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
8702000
CY2023Q1 cprx Asset Acquisation Due To Licensor Current
AssetAcquisationDueToLicensorCurrent
12928000
CY2022Q4 cprx Asset Acquisation Due To Licensor Current
AssetAcquisationDueToLicensorCurrent
13127000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
279000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
238000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53318000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53613000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3468000
CY2023Q1 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
70175000
CY2022Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
71234000
CY2023Q1 cprx Period Of Collaboration Agreement
PeriodOfCollaborationAgreement
P10Y
CY2022Q1 cprx Revenue Recognition Method Recognized
RevenueRecognitionMethodRecognized
0
CY2023Q1 cprx Revenue Recognition Method Recognized
RevenueRecognitionMethodRecognized
0
CY2023Q1 cprx Number Of Trading Days From Receipt Of The Notice Letter
NumberOfTradingDaysFromReceiptOfTheNoticeLetter
P45D
CY2023Q1 cprx Percentage Of Royalty Payable To Net Sales
PercentageOfRoyaltyPayableToNetSales
0.035
CY2023Q1 cprx Purchase Price Consideration For Intangible Assets Acquired
PurchasePriceConsiderationForIntangibleAssetsAcquired
33569000
CY2023Q1 cprx Acquired Research And Development Inventory Expensed From Asset Acquisition
AcquiredResearchAndDevelopmentInventoryExpensedFromAssetAcquisition
4130000
CY2023Q1 cprx Asset Acquisition Value
AssetAcquisitionValue
37699000
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.208
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.242
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q1 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2022Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
105938292
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
105938292
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
105263031
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
105263031
CY2023Q1 cprx Number Of Votes Entitlement For Each Share Held By Common Stock Holders
NumberOfVotesEntitlementForEachShareHeldByCommonStockHolders
1
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2600000
CY2023Q1 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
0
CY2022Q1 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
6.38
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2892000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1903000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12082183

Files In Submission

Name View Source Status
cprx-20230331_def.xml Edgar Link unprocessable
0001193125-23-140701-index-headers.html Edgar Link pending
0001193125-23-140701-index.html Edgar Link pending
0001193125-23-140701.txt Edgar Link pending
0001193125-23-140701-xbrl.zip Edgar Link pending
cprx-20230331.xsd Edgar Link pending
d499325d10q.htm Edgar Link pending
d499325dex311.htm Edgar Link pending
d499325dex312.htm Edgar Link pending
d499325dex321.htm Edgar Link pending
d499325dex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
cprx-20230331_cal.xml Edgar Link unprocessable
cprx-20230331_lab.xml Edgar Link unprocessable
cprx-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
d499325d10q_htm.xml Edgar Link completed
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending